ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $3.50 Consensus PT from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $3.50.

Several equities analysts recently issued reports on the company. Jefferies Financial Group initiated coverage on ALX Oncology in a research report on Thursday, November 13th. They issued a “buy” rating and a $4.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALX Oncology in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Monday, December 22nd.

ALX Oncology Price Performance

Shares of ALXO stock opened at $1.24 on Friday. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.13. ALX Oncology has a 12-month low of $0.40 and a 12-month high of $2.27. The firm has a fifty day moving average of $1.36 and a 200-day moving average of $1.15. The firm has a market capitalization of $67.23 million, a price-to-earnings ratio of -0.61 and a beta of 0.51.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04). On average, equities research analysts forecast that ALX Oncology will post -2.76 earnings per share for the current year.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently modified their holdings of ALXO. Invesco Ltd. acquired a new position in shares of ALX Oncology during the first quarter worth about $46,000. Nuveen LLC bought a new stake in ALX Oncology in the 1st quarter valued at approximately $103,000. AQR Capital Management LLC boosted its position in ALX Oncology by 183.6% during the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after acquiring an additional 77,065 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after acquiring an additional 186,883 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of ALX Oncology in the second quarter valued at approximately $84,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.